A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with newly diagnosed multiple myeloma (NDMM)
Phase of Trial: Phase I/II
Latest Information Update: 22 Aug 2017
At a glance
- Drugs Durvalumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 10 Jul 2017 Planned number of patients changed from 138 to 120.
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 According to trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology, 15 patients have been enrolled till date.